|
[Related PubMed/MEDLINE]
Total Number of Papers: 25
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model. |
RVO, Sema3A, TNF |
| 2 |
2022 |
Recurrent Pterygium: A Review. |
CAU, MMC |
| 3 |
2022 |
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. |
cfDNA, EGFR, NSCLC, TKIs |
| 4 |
2022 |
State of the art spatial visualization of the response of neovascularisation to anti-vascular endothelial growth factor therapy. |
MacTel, OCTA, RNV, RNV |
| 5 |
2022 |
Subthreshold Photocoagulation, Laser Endpoint Management Based on Optical Coherence Tomography Angiography in Cases of Diabetic Macular Edema Refractory to Anti-VEGF. |
BCVA, CMT, CVI, DCP, DME, EDI-OCT, EpM, ETDRS, FAF, FAZ, LA, logMAR, OCTA, SA, SCP, SFCT, TCA, VDs |
| 6 |
2022 |
The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study. |
nAMD |
| 7 |
2021 |
Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis. |
nAMD, NMA, RCTs |
| 8 |
2021 |
Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. |
nAMD |
| 9 |
2021 |
Dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema: real-world data versus clinical trials outcomes. |
BCVA, CMT, DME, IOP |
| 10 |
2021 |
Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. |
--- |
| 11 |
2021 |
Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study. |
DME |
| 12 |
2020 |
Biomarkers for central serous chorioretinopathy. |
CMD, CME, CSCR, CT, CVI, OCT |
| 13 |
2020 |
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. |
nAMD |
| 14 |
2020 |
Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN) and Follow-Up Considerations/Recommendations. |
DME, FAc |
| 15 |
2020 |
Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients. |
DME |
| 16 |
2019 |
Prevention of macular edema in patients with diabetes after cataract surgery. |
PCME |
| 17 |
2019 |
Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. |
EMR, nAMD |
| 18 |
2018 |
Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro. |
DDS |
| 19 |
2018 |
Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema. |
CSMT, DME, SD-OCT |
| 20 |
2018 |
Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit. |
OAP, SPSS |
| 21 |
2018 |
[Systemic safety following intravitreal injections of anti-VEGF]. |
AEs |
| 22 |
2016 |
Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. |
iCRVO |
| 23 |
2014 |
Laser photocoagulation for proliferative diabetic retinopathy. |
BCVA, CI, ICTRP, mRCT, RCTs, RR, WHO |
| 24 |
2014 |
The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. |
AMD |
| 25 |
2013 |
Branch retinal vein occlusion: treatment modalities: an update of the literature. |
--- |
|
A Search Service for Abbreviation / Long Form
